Cargando…

Respective Prognostic Value of Genomic Grade and Histological Proliferation Markers in Early Stage (pN0) Breast Carcinoma

BACKGROUND: Genomic grade (GG) is a 97-gene signature which improves the accuracy and prognostic value of histological grade (HG) in invasive breast carcinoma. Since most of the genes included in the GG are involved in cell proliferation, we performed a retrospective study to compare the prognostic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reyal, Fabien, Bollet, Marc A., Caly, Martial, Gentien, David, Carpentier, Sabrina, Peyro-Saint-Paul, Hélène, Pierga, Jean-Yves, Cottu, Paul, Dieras, Véronique, Sigal-Zafrani, Brigitte, Vincent-Salomon, Anne, Sastre-Garau, Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329444/ https://www.ncbi.nlm.nih.gov/pubmed/22529987 http://dx.doi.org/10.1371/journal.pone.0035184

Ejemplares similares

Correction: Respective Prognostic Value of Genomic Grade and Histological Proliferation Markers in Early Stage (pN0) Breast Carcinoma
por: Reyal, Fabien, et al.
Publicado: (2012)

Long-Term Prognostic Performance of Ki67 Rate in Early Stage, pT1-pT2, pN0, Invasive Breast Carcinoma
por: Reyal, Fabien, et al.
Publicado: (2013)

Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay
por: Mouttet, D., et al.
Publicado: (2016)

External Validation of Adjuvant! Online Breast Cancer Prognosis Tool. Prioritising Recommendations for Improvement
por: Hajage, David, et al.
Publicado: (2011)

Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR-positive/HER2-negative breast carcinoma
por: Daveau, C, et al.
Publicado: (2014)

The Molecular Subtype Classification Is a Determinant of Sentinel Node Positivity in Early Breast Carcinoma
por: Reyal, Fabien, et al.
Publicado: (2011)

Are ipsilateral breast tumour invasive recurrences in young (⩽40 years) women more aggressive than their primary tumours?
por: Sigal-Zafrani, B, et al.
Publicado: (2007)

Epigenomic Alterations in Breast Carcinoma from Primary Tumor to Locoregional Recurrences
por: Moarii, Matahi, et al.
Publicado: (2014)

Non-Sentinel Lymph Node Metastasis Prediction in Breast Cancer with Metastatic Sentinel Lymph Node: Impact of Molecular Subtypes Classification
por: Reyal, Fabien, et al.
Publicado: (2012)

HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?
por: Vincent-Salomon, A, et al.
Publicado: (2007)

Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2017)

Genomic Instability: A Stronger Prognostic Marker Than Proliferation for Early Stage Luminal Breast Carcinomas
por: Vincent-Salomon, Anne, et al.
Publicado: (2013)

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2015)

Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance
por: Choesmel, Valérie, et al.
Publicado: (2004)

Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2016)

Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment
por: Bollet, Marc A, et al.
Publicado: (2009)

High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies
por: Bollet, M A, et al.
Publicado: (2008)

Bilateral Poly Implant Prothèse Implant Rupture: An Uncommon Presentation
por: Mallon, Peter, et al.
Publicado: (2013)

Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy
por: Baulies, S, et al.
Publicado: (2015)

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
por: Hamy, Anne-Sophie, et al.
Publicado: (2018)

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
por: Hamy-Petit, Anne-Sophie, et al.
Publicado: (2016)

Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity
por: Vincent-Salomon, Anne, et al.
Publicado: (2007)

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
por: Jacot, William, et al.
Publicado: (2019)

Molecular profiling of patient-derived breast cancer xenografts
por: Reyal, Fabien, et al.
Publicado: (2012)

Key Members of the CmPn as Biomarkers Distinguish Histological and Immune Subtypes of Hepatic Cancers
por: Abou-Fadel, Johnathan, et al.
Publicado: (2023)

NCLEX-PN®
por: Gardner, Wilda
Publicado: (2017)

Human Papillomavirus Mutational Insertion: Specific Marker of Circulating Tumor DNA in Cervical Cancer Patients
por: Campitelli, Maura, et al.
Publicado: (2012)

Bismuth Amides Mediate Facile and Highly Selective Pn–Pn Radical‐Coupling Reactions (Pn=N, P, As)
por: Oberdorf, Kai, et al.
Publicado: (2021)

Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models
por: Laas, E, et al.
Publicado: (2015)

A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer
por: Meyniel, Jean-Philippe, et al.
Publicado: (2010)

8p22 MTUS1 Gene Product ATIP3 Is a Novel Anti-Mitotic Protein Underexpressed in Invasive Breast Carcinoma of Poor Prognosis
por: Rodrigues-Ferreira, Sylvie, et al.
Publicado: (2009)

El test PN
por: Corman, Louis, 1901-
Publicado: (1985)

Low expression of bcl-2 in Brca1-associated breast cancers
por: Freneaux, P, et al.
Publicado: (2000)

PnAn13, an antinociceptive synthetic peptide inspired in the Phoneutria nigriventer toxin PnTx4(6–1) (δ-Ctenitoxin-Pn1a)
por: Emerich, Bruna Luiza, et al.
Publicado: (2020)

NCLEX®-PN Exam Prep
por: Rinehart, Wilda
Publicado: (2011)

NCLEX®-PN Exam Prep
por: Rinehart, Wilda
Publicado: (2014)

NCLEX-PN® Exam Cram
por: Gardner, Wilda
Publicado: (2014)

NCLEX-PN exam cram
por: Rinehart, Wilda, et al.
Publicado: (2012)

NCLEX-PN exam cram
por: Rinehart, Wilda, et al.
Publicado: (2008)

NCLEX-PN practice questions
por: Rinehart, Wilda, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_3m4c99f350ngof9h16oo6d0ugh